Regeneron Pharmaceuticals Inc $316.22

down -5.96


31/7/2014 04:00 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has outperformed the S&P 500 by 1%

Partner Headlines

  1. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD
  2. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  3. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  4. Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples

    IBD
  5. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  6. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  7. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  8. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  9. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following ...

    Benzinga
  10. Benzinga's Top #PreMarket Gainers

    Benzinga
  11. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  12. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  13. Pharmas Soar To New Highs

    IBD
  14. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  15. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  16. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  17. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  18. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  19. EYLEA Injection Recommended For Approval Regarding Treatment Of Visual ...

    Benzinga
  20. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  21. Major Indexes Narrowly Lower As Actavis Rallies

    IBD
  22. Regeneron Shares Fall Following BMO's Note Of Roche Preference

    Benzinga
  23. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  24. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  25. Valeant EPS Tops, Sales Miss

    IBD
  26. Valeant Reports Mixed Q1 Amid Drug Earnings Bonanza

    IBD
  27. Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

    IBD
  28. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  29. RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

    Benzinga
  30. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  31. Benzinga's Top Initiations

    Benzinga
  32. Top 40 Upcoming Earnings Releases

    Benzinga
  33. Biotechs Struggling To Find A Bottom

    Benzinga
  34. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  35. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  36. Cholesterol drug meets goal

    IBD
  37. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  38. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  39. Gilead Adds To Biotech Woes

    IBD
  40. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  41. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  42. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  43. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  44. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  45. US Stock Futures Rise; GDP, Jobless Claims Data In Focus

    Benzinga
  46. Netflix, Other Big Cap Growth Stocks Offer Buy Points

    IBD
  47. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  48. UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

    Benzinga
  49. Regeneron falls on FDA probe

    IBD
  50. Nasdaq Lags As Stock Market Closes Lower

    IBD
Trading Center